Recruiting NA INTERVENTIONAL 1-arm
NCT06717022
A Clinical Study of CHT102 in Mesothelin Positive Advanced Solid Tumors
A Clinical Study of CHT102, a Universal Chimeric Antigen Receptor T-Cell Immunotherapy(U CAR-T) for Mesothelin(MSLN) Positive Advanced Solid Tumors: a Single-arm, Open-label, Dose Escalation and Expansion Clinical Study
Sponsor: Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
Conditions
Mesothelin Positive Tumors
Interventions
CHT102 allogeneic CAR T cells
Updated 1 time since 2025 Last updated: Nov 29, 2024 Started: May 6, 2024 Primary completion: Jun 30, 2026 Completion: May 31, 2039
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A NA clinical study on Mesothelin Positive Tumors, this trial is actively recruiting participants. The trial is conducted by Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd. and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Recruiting — NA
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Nanjing Calmhome Cell and Gene Engineering Institute Co., Ltd.
- Tianjin Medical University Cancer Institute and Hospital
Data source: Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .